Global assessment and itch/scratch scores highlight the effectiveness of topical roflumilast for treating atopic dermatitis in children 3 months to 2 years old, in a phase 2 study.
Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the INTEGUMENT programZORYVE cream improved signs and symptoms o ...
If you’re a person of color, finding the right treatment for atopic dermatitis, a common form of eczema, can be challenging. Even though the disease is more prevalent in Black Americans than white ...
WESTLAKE VILLAGE, Calif. and ORLANDO, Fla., March 07, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (ARQT) (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing ...
Data from the INTEGUMENT trials demonstrates that ZORYVE cream 0.15% has a favorable safety profile and high tolerability, even among patients with prior inadequate responses to traditional treatments ...
If you suspect that you or your child may have atopic dermatitis -- a chronic inflammatory skin disease that is the most common form of eczema -- make an appointment with your pediatrician or family ...
Add Yahoo as a preferred source to see more of our stories on Google. As the weather changes, have you been itching and scratching at the crooks of your knees and elbows? Eczema, also known as atopic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results